Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ireland-based Actavis has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya Gel, 1.2%/2.5%.
Subscribe to our email newsletter
Acanya (clindamycin phosphate and benzoyl peroxide) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
As part of the deal, Valeant will grant Actavis a license to market its generic Acanya Gel beginning in 01 July 2018 or earlier under certain circumstances.
Launch of Actavis’ product is contingent upon the company securing final approval from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic Acanya Gel.
In addition, Valeant’s subsidiaries Valeant Canada and Valeant International Bermuda have entered into an agreement with Actavis Pharma to settle outstanding patent litigation related to the generic version of Actavis’ Tiazac XC (diltiazem hydrochloride) 180 mg/240mg/300mg/360 mg capsules.
Actavis is a developer and manufacturer of generic, brand, branded generic, legacy brands and over-the-counter (OTC) pharmaceutical products.